• Dose expansion Cohorts:

• Cohort B (Burkitt):

• Participants must have a diagnosis of relapsed or refractory Burkitt Lymphoma

‣ Participants with Burkitt lymphoma must have relapsed or failed to respond to at least 1 prior line of multiagent chemoimmunotherapy with prior exposure to both an anti-CD20 antibody agent and an anthracycline.

⁃ No significant circulating disease, defined as an elevated total lymphocyte count above the upper limit of normal (ULN) due to the presence of malignant cells.

• Participants must have measurable disease as defined below:

‣ Participants with Burkitt Lymphoma must have Positron Emission Tomography (PET)-positive disease according to Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

• Cohort M/W (Marginal/Waldenström):

• Participants must have a diagnosis of relapsed or refractory Marginal Zone Lymphoma (MZL), or Lymphoplasmacytic Lymphoma (LPL)/Waldenström Macroglobulinemia (WM):

• o Participants with indolent lymphomas (nodal or extranodal marginal zone lymphoma, and lymphoplasmacytic lymphoma) must have relapsed after or have been refractory to ≥ 2 prior lines of multi-agent chemoimmunotherapy including prior exposure to an anti-CD20 antibody and an alkylating agent.

• Participants must have measurable disease as defined below:

• o Participants with Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: must either have PET-positive disease according to Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification or serum monoclonal immunoglobulin M (IgM) paraprotein \> 0.5 g/dL.

• Participants with indolent lymphoma (Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia) must have symptomatic disease necessitating systemic treatment.

• In addition, all participants must meet the following criteria:

• CD19-positive by either immunohistochemistry or flow cytometry analysis on any biopsy. If prior anti-CD19 therapy has been administered, CD19-positivity has to be re-established on the most recent biopsy.

• Age ≥18 years at the time of consent.

• Absolute lymphocyte count \> 100/UL.

• Eastern Cooperative Oncology Group (ECOG) performance status \< 2.

• Adequate organ function, defined as:

∙ Adequate bone marrow function for apheresis and lymphodepleting chemotherapy

‣ Hemoglobin \>8 gm/dl (transfusions allowed)

‣ Platelets \>50,000/uL (transfusions allowed)

‣ Absolute Neutrophil Count (ANC) \> 500/uL

‣ alanine aminotransferase (ALT)/aspartate aminotransferase (AST) \< 3 x institutional upper limit of normal (ULN) and Total bilirubin \< 1.5 mg/dl x institutional ULN, except with Gilbert's syndrome

‣ Serum Creatinine \< 2 x the institutional ULN

‣ Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) \> 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA) within 3 months of screening. Repeat testing may occur at Investigator's discretion.

• Adequate vascular access for leukapheresis procedure (either peripheral line or surgically placed line).

• Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must have a negative serum or urine pregnancy test AND agree to use highly effective methods of contraception for 1 year after the last dose of anti-CD19 CAR-T cells.

• Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method.

• Ability to understand a written informed consent document, and the willingness to sign it.